Association of Asprosin in Periodontitis and Acute Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between cardiovascular diseases and periodontitis. Investigators postulated that asprosin may be a candidate for explaining the triangular relationship between cardiovascular and periodontal disease.

Detailed Description
-----------------
Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Cardiovascular and periodontal diseases are closely related, presenting a triad association. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activatesinvestigators the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation.

Official Title
-----------------
Serum Asprosin Concentrations in Patients With Periodontitis and Acute Coronary Syndrome

Conditions
-----------------
Cardiovascular Diseases, Periodontal Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For Healthy group All individuals were generally healthy, non-smoking For Myocard Infarctus group patients with ST elevation of Myocardial Infactus patient with less than ten teeth Exclusion Criteria: Smokers or those with diabetes or other inflammatory disease Pregnant or breastfeeding women None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months. None has a contagious disease such as HIV or AIDS

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Group<br>70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients. | Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis<br>* Serum samples will be collected from both groups for biochemical analysis.<br>|
| Myocard Infactus Group<br>50 patients with myocardial infarction; 25 healthy gingiva is divided into 2 subgroups, 25 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients. | Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis<br>* Serum samples will be collected from both groups for biochemical analysis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asprosin Levels | Determination of asprosin levels by making biochemical analyzes from serum | two weeks |